Clinical trial NCT03146078: Rate of Progression in USH2A-related Retinal Degeneration
Official title: Rate of Progression in USH2A-related Retinal Degeneration
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Usher Syndrome, Type 2A
Retinitis Pigmentosa 39
Lead sponsor: Jaeb Center for Health Research
Sponsor class: OTHER
Collaborators: name: Foundation Fighting Blindness
First posted: 2017-05-09
Enrollment: 127
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Potential eligibility will be assessed during a routine examination by an investigator prior to obtaining informed consent, as part of usual care

Brief summary: The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or non-syndromic retinitis pigmentosa (RP39).

RUSH2A Extension Study: The purpose of this addendum is to extend RUSH2A to 7- and 9-year visits, with the goal to use longer term data to further develop and support early candidate endpoints as possible clinical trial outcomes.

Detailed description: This natural history study of patients with USH2A mutations will accelerate the development of outcome measures for clinical trials. Sensitive, objective outcome measures of retinal degeneration will greatly facilitate development of treatments for Usher syndrome patients. Together these approaches are expected to have an impact on understanding USH2A-related retinal degeneration, developing experimental treatment protocols, and assessing their effectiveness.

The goals and expected impact of this natural history study are to:

1. Report the natural history of retinal degeneration in patients with biallelic mutations in the USH2A gene
2. Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials in USH2A-related retinal degeneration
3. Identify well-defined subpopulations for future clinical trials of investigative treatments for USH2A-related retinal degeneration

Study Objectives

The primary objectives of the natural history study are to:

1. Characterize the natural history of retinal degeneration associated with biallelic pathogenic mutations in the USH2A gene over 4 years, as measured using functional outcome measures (static perimetry, microperimetry, full-field stimulus threshold (FST), electroretinography (ERG), and visual acuity)
2. Characterize the natural history of retinal degeneration associated with biallelic pathogenic mutations in the USH2A gene over 4 years, as measured using structural outcome measures (spectral-domain optical coherence tomography (SD-OCT) ellipsoid zone (EZ) area)
3. Investigate structure-function relationships for insights into the mechanisms of retinal degeneration by relating changes in SD-OCT EZ area to visual field progression in individuals with biallelic pathogenic mutations in the USH2A gene
4. Assess for possible genotype, phenotype, and environmental risk factors with progression of the outcome measures at 4 years in individuals with biallelic pathogenic mutations in the USH2A gene

Some additional secondary objectives of this study include:

1. Characterize baseline cross-sectional retinal degeneration associated with biallelic pathogenic mutations in the USH2A gene (as measured using the main outcome measures)
2. Investigate comorbidities associated with disease (baseline cross-sectional) and disease progression (longitudinal natural history study) in individuals with biallelic pathogenic mutations in the USH2A gene
3. Explore patient reported outcome (PRO) measures associated with disease (baseline cross-sectional) and disease progression (longitudinal natural history study) in individuals with biallelic pathogenic mutations in the USH2A gene
4. Evaluate variability and symmetry of left and right eye kinetic perimetry and SD-OCT outcomes at baseline and at 4 years in individuals with biallelic pathogenic mutations in the USH2A gene

RUSH2A Extension Study:

Extension Study Objectives:

Objectives of the RUSH2A Extension Study include evaluating the original study objectives over the longer term (progression on structural and functional outcomes, correlation of progression among outcomes, and factors related to progression) as well as correlating early changes of microperimetry slope, static perimetry slope, full-field stimulus threshold with longer term clinically meaningful outcomes (possible design of early endpoint / late endpoint proposal for FDA). As part of this effort, we are adding virtual reality mobility course testing to RUSH2A as an ancillary study, for a subset of sites, to evaluate its role as a clinically meaningful outcome in future trials.

Virtual Reality (VR) Ancillary Study:

VR Objectives: Specific objectives of VR as part of the RUSH2A Extension Study include:

Correlate early changes of microperimetry, static perimetry, full-field stimulus threshold with longer term clinically meaningful outcomes (possible design of early endpoint / late endpoint proposal for FDA).

Measure changes in progression of disease on VR outcomes, from 7-year to 9-year visit.

Work out logistical issues of multi-center implementation of VR setup and procedures for future trials.

Eligibility criteria: Inclusion Criteria:

* Willing and able to complete the informed consent process
* Ability to return for all study visits over 48 months if in the natural history study
* Age ≥ 8 years
* At least 2 pathogenic or likely pathogenic mutations in USH2A gene from a clinically certified lab report

Ocular Inclusion Criteria

Both eyes must meet all of the following:

* Clinical diagnosis of a rod-cone degeneration
* Clear ocular media and adequate pupil dilation to permit good quality photographic imaging
* Ability to perform kinetic and static perimetry reliably

Exclusion Criteria:

* Mutations in genes that cause autosomal dominant RP, X-linked RP, or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than USH2A
* Expected to enter experimental treatment trial at any time during this study
* History of more than 1 year of cumulative treatment, at any time, with an agent associated with pigmentary retinopathy (including hydroxychloroquine, chloroquine, thioridazine, and deferoxamine)

Ocular Exclusion Criteria

If either eye has any of the following, the patient is not eligible:

* Current vitreous hemorrhage
* Current or any history of rhegmatogenous retinal detachment
* Current or any history of (e.g., prior to cataract or refractive surgery) spherical equivalent of the refractive error worse than -8 Diopters of myopia
* History of intraocular surgery (e.g., cataract surgery, vitrectomy, penetrating keratoplasty, or LASIK) within the last 3 months
* Current or any history of confirmed diagnosis of glaucoma (e.g., based on glaucoma visual field, nerve changes, or glaucoma filtering surgery)
* Current or any history of retinal vascular occlusion or proliferative diabetic retinopathy
* Expected to have cataract removal surgery during the study
* History or current evidence of ocular disease that, in the opinion of the investigator, may confound assessment of visual function
* History of treatment for retinitis pigmentosa that could affect the progression of retinal degeneration (including participation in a clinical trial within the last year or a retained drug delivery device)

Primary outcomes:
measure: Characterize Change using Visual Field Sensitivity
timeFrame: Baseline and every year until study completion (4 years)
measure: Characterize Change using Visual Acuity
timeFrame: Baseline and every year until study completion (4 years)
measure: Characterize Change using Mean Retinal Sensitivity
timeFrame: Baseline and every year until study completion (4 years)
measure: Characterize Change in EZ area
timeFrame: Baseline and every year until study completion (4 years)
measure: Characterize Change in Rod- and cone-mediated retinal function
timeFrame: Baseline and every year until study completion (4 years)
measure: Characterize Change in Retinal function
timeFrame: Baseline and after four years
Secondary outcomes:
measure: MOST-VR Mobility Testing
timeFrame: Seven and nine year visits
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco
state: California
city: Gainesville
country: United States
facility: Vitreo-Retinal Associates
state: Florida
city: Baltimore
country: United States
facility: Wilmer Eye Institute at Johns Hopkins
state: Maryland
city: Boston
country: United States
facility: Massachusetts Eye and Ear
state: Massachusetts
city: Ann Arbor
country: United States
facility: Kellogg Eye Center, University of Michigan
state: Michigan
city: Durham
country: United States
facility: Duke University Eye Center
state: North Carolina
city: Portland
country: United States
facility: OHSU Casey Eye Institute
state: Oregon
city: Dallas
country: United States
facility: Retina Foundation of the Southwest
state: Texas
city: Houston
country: United States
facility: Baylor Eye Physicians and Surgeons
state: Texas
city: Salt Lake City
country: United States
facility: Moran Eye Center, University of Utah
state: Utah
city: Milwaukee
country: United States
facility: Medical College of Wiconsin
state: Wisconsin
city: Toronto
country: Canada
facility: Hospital for Sick Children
city: Paris
country: France
facility: Centre hospitalier National d'Ophtalmologie des Quinze-Vingts
city: Tübingen
country: Germany
facility: University of Tubingen
city: Nijmegen
country: Netherlands
facility: Radboud University
city: London
country: United Kingdom
facility: Moorfields Eye Hospital
Study officials:
affiliation: University of California, San Francisco
name: Jacque Duncan, MD
role: STUDY_CHAIR
References: